Guangzhou Ruiao Biopharmaceutical Technology

Guangzhou Ruiao Biopharmaceutical Technology is a China-based biopharmaceutical subsidiary of ApicHope focused on innovative drug investment, development, and strategic holding activities. The company became visible through its joint venture with Arthrosi Therapeutics to establish Guangzhou Ruianbo Pharmaceutical Technology for development of AR882 in Greater China and to advance AR035 for EGFR exon 20-mutant non-small cell lung cancer. Ruiao also holds and has increased ownership in Guangdong South China Vaccine Co., indicating involvement in vaccine-related biopharmaceutical assets. Based on public disclosures, Ruiao appears to function primarily as an operating and investment vehicle within ApicHope’s innovative medicines strategy rather than as a standalone publicly listed drug developer. Its disclosed activities center on small-molecule innovation and vaccine-related equity holdings in China.